The Board of Directors Approved the Appointment
of the Chief Scientific Officer
Date of events
2022/08/11
To which item it meets
paragraph 8
Statement
1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Chief Scientific Officer (CSO)
2.Date of occurrence of the change:2022/08/11
3.Name, title, and resume of the previous position holder:N/A
4.Name, title, and resume of the new position holder:Lih-Ling Lin /
Chief Scientific Officer / The Head of Checkpoint Immunology Cluster
in Immunology and Inflammation Research Area at Sanofi
5.Type of change (please enter: "resignation",
"position adjustment", "dismissal", "retirement",
"death" or "new replacement"):New appointment
6.Reason for the change:New appointment
7.Effective date:2022/08/01
8.Any other matters that need to be specified:
The new appointment of the Chief Scientific Officer was disclosed in
the Company's material information on August 1, 2022, and was approved
by the Board of Directors on August 11, 2022.
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEssentia Corporation published this content on 11 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2022 10:23:04 UTC.
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Companyâs products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
PHARMAESSENTIA CORPORATION 
